| Literature DB >> 10704711 |
M C Perry1, D C Ihde, J E Herndon, M L Grossbard, S J Grethein, J N Atkins, E E Vokes, M R Green.
Abstract
In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a 'proof of principle' that non-cisplatin containing regimens also have activity in this setting.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10704711 DOI： 10.1016/s0169-5002(99)00129-4
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705